ZIVO Bioscience develops therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures. News about ZIVO centers on its biotech and agtech R&D platform, Zivolife™ algal biomass for human nutrition, and animal-health applications built around proprietary active ingredients, algal and bacterial strains, and cultivation and production techniques.
Company updates commonly cover commercial manufacturing and distribution relationships, poultry health research, University of Delaware studies involving low pathogenicity avian influenza, coccidiosis treatment licensing discussions, immune-enhancing biologics for poultry, shareholder communications, capital needs, and public-company reporting status.
KEEGO HARBOR, Mich., March 11, 2021 – ZIVO Bioscience (OTCQB: ZIVO) announced that CEO Andrew A. Dahl will present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can view his corporate presentation post-registration and request one-on-one meetings. ZIVO focuses on R&D of therapeutic products derived from proprietary algal cultures aimed at health benefits, particularly for autoimmune and inflammatory responses. Forward-looking statements highlight risks and uncertainties around product commercialization and market acceptance.